Protagonist Therapeutics, Inc. (PTGX)
NASDAQ
Market Cap
$1.86B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
718 of 809
Rank in Industry
388 of 445
Largest Insider Buys in Sector
PTGX Stock Price History Chart
PTGX Stock Performance
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Insider Activity of Protagonist Therapeutics, Inc.
Over the last 12 months, insiders at Protagonist Therapeutics, Inc. have bought $0 and sold $6.03M worth of Protagonist Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protagonist Therapeutics, Inc. have bought $908,814 and sold $2.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 24,000 shares for transaction amount of $160,800 was made by SELICK HAROLD E (director) on 2020‑03‑12.
List of Insider Buy and Sell Transactions, Protagonist Therapeutics, Inc.
| 2024-06-07 | Sale | PATEL DINESH V PH D | President and CEO | 35,000 0.0603% | $35.19 | $1.23M | -6.35% | |
| 2024-06-07 | Sale | Waddill William D. | director | 8,000 0.0137% | $35.00 | $280,000 | -6.35% | |
| 2024-04-18 | Sale | Ali Asif | Chief Financial Officer | 1,234 0.0021% | $25.11 | $30,986 | +18.43% | |
| 2024-04-01 | Sale | PATEL DINESH V PH D | President and CEO | 25,000 0.0429% | $28.31 | $707,750 | -0.14% | |
| 2024-03-01 | Sale | PATEL DINESH V PH D | President and CEO | 30,000 0.051% | $31.62 | $948,600 | -10.36% | |
| 2024-03-01 | Sale | Ali Asif | Chief Financial Officer | 14,248 0.0247% | $32.24 | $459,318 | -10.36% | |
| 2024-03-01 | Sale | Waddill William D. | director | 12,975 0.0219% | $31.34 | $406,637 | -10.36% | |
| 2024-02-29 | Sale | Ali Asif | Chief Financial Officer | 9,939 0.0174% | $30.69 | $305,048 | -4.93% | |
| 2024-01-09 | Sale | Gupta Suneel | Chief Development Officer | 5,000 0.0084% | $25.00 | $125,000 | +8.95% | |
| 2023-12-13 | Sale | PATEL DINESH V PH D | President and CEO | 75,000 0.1305% | $20.08 | $1.51M | +39.33% | |
| 2023-11-15 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 1,848 0.0032% | $16.24 | $30,012 | +64.57% | |
| 2021-12-21 | Sale | PATEL DINESH V PH D | President and CEO | 15,000 0.0311% | $32.14 | $482,171 | -70.97% | |
| 2021-08-17 | Sale | Liu David Y | Chief Scientific Officer | 14,779 0.0303% | $47.56 | $702,889 | -47.52% | |
| 2021-02-11 | Sale | Noonberg Sarah B. | director | 3,700 0.0084% | $25.09 | $92,833 | +29.81% | |
| 2021-02-10 | Sale | Noonberg Sarah B. | director | 4,700 0.011% | $25.47 | $119,722 | +32.45% | |
| 2021-01-19 | Sale | PATEL DINESH V PH D | President and CEO | 24,846 0.0557% | $24.60 | $611,105 | +31.22% | |
| 2020-08-11 | Sale | KHOSLA CHAITAN PHD | director | 2,499 0.0068% | $17.19 | $42,952 | +47.14% | |
| 2020-03-12 | SELICK HAROLD E | director | 24,000 0.0869% | $6.70 | $160,800 | +198.80% | ||
| 2019-12-03 | PATEL DINESH V PH D | President and CEO | 60,000 0.2602% | $5.62 | $337,000 | +243.28% | ||
| 2019-12-03 | Gupta Suneel | EVP Clinical Operations | 60,000 0.2377% | $5.13 | $307,800 | +243.28% |
Insider Historical Profitability
126.31%
| PATEL DINESH V PH D | President and CEO | 515415 0.9264% | $31.76 | 1 | 11 | +243.28% |
| Gupta Suneel | Chief Development Officer | 187567 0.3252% | $31.76 | 1 | 1 | +243.28% |
| Ali Asif | Chief Financial Officer | 37163 0.0666% | $31.76 | 0 | 3 | |
| MOLINA ARTURO MD | Chief Medical Officer | 22527 0.0391% | $31.76 | 0 | 1 | |
| Waddill William D. | director | 12000 0.0208% | $31.76 | 0 | 2 | |
| Papanek Julie | director | 2453255 4.2534% | $31.76 | 1 | 0 | +18.24% |
| JOHNSON & JOHNSON | 10 percent owner | 2449183 4.2463% | $31.76 | 1 | 0 | +18.24% |
| CANAAN X L.P. | 10 percent owner | 2116552 3.6696% | $31.76 | 1 | 13 | +18.24% |
| Shanafelt Armen | 2099482 3.64% | $31.76 | 1 | 0 | +18.24% | |
| LV Management Group, LLC | 10 percent owner | 2099482 3.64% | $31.76 | 1 | 0 | +18.24% |
| Liu David Y | Chief Scientific Officer | 58254 0.101% | $31.76 | 0 | 12 | |
| Shames Richard S. | Chief Medical Officer | 32021 0.0555% | $31.76 | 0 | 6 | |
| SELICK HAROLD E | director | 15310 0.0265% | $31.76 | 1 | 0 | +198.8% |
| Giraudo Bryan | director | 8000 0.0139% | $31.76 | 2 | 0 | +243.28% |
| Kalkofen Donald A. | Chief Financial Officer | 1175 0.002% | $31.76 | 1 | 0 | +243.28% |
| O'Neil Thomas P. | Chief Financial Officer | 0 0% | $31.76 | 0 | 1 | |
| Noonberg Sarah B. | director | 0 0% | $31.76 | 0 | 2 | |
| KHOSLA CHAITAN PHD | director | 0 0% | $31.76 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Farallon Capital | $166.03M | 9.79 | 5.74M | +0.08% | +$131,428.99 | 1.16 | |
| BlackRock | $161.13M | 9.5 | 5.57M | +0.46% | +$740,116.19 | <0.01 | |
| RTW Investments, LP | $153.78M | 9.06 | 5.32M | 0% | +$0 | 2.27 | |
| Bvf Inc Il | $108.66M | 6.4 | 3.76M | -34.62% | -$57.54M | 0.8 | |
| State Street | $94.67M | 5.58 | 3.27M | +19.87% | +$15.7M | <0.01 | |
| The Vanguard Group | $92.37M | 5.44 | 3.19M | +1.24% | +$1.13M | <0.01 | |
| Johnson & Johnson | $70.85M | 4.18 | 2.45M | 0% | +$0 | 1.61 | |
| Adage Capital Partners Gp L L C | $64.19M | 3.78 | 2.22M | +71.78% | +$26.82M | 0.12 | |
| Morgan Stanley | $54.38M | 3.21 | 1.88M | +57.73% | +$19.91M | <0.01 | |
| Cowen Group | $45.06M | 2.66 | 1.56M | New | +$45.06M | 1.43 | |
| Geode Capital Management | $37.43M | 2.21 | 1.29M | +3.64% | +$1.32M | <0.01 | |
| Point72 Asset Management | $34.71M | 2.05 | 1.2M | -54.09% | -$40.89M | 0.07 | |
| Jefferies Financial Group | $34.15M | 2.01 | 1.18M | -7.08% | -$2.6M | 0.62 | |
| Kynam Capital Management Lp | $33.1M | 1.95 | 1.14M | -42.93% | -$24.9M | 0.42 | |
| Perceptive Advisors | $28.77M | 1.7 | 994,323 | +159.44% | +$17.68M | 0.02 | |
| Marshall Wace | $28.26M | 1.67 | 976,893 | +585.68% | +$24.14M | 0.04 | |
| Fairmount Funds Management LLC | $26.96M | 1.59 | 931,890 | New | +$26.96M | 2.94 | |
| Deutsche Bank | $26.35M | 1.55 | 910,806 | +0.09% | +$22,970.42 | 0.01 | |
| T. Rowe Price | $23.7M | 1.4 | 819,296 | -0.54% | -$128,569.08 | <0.01 | |
| Dimensional Fund Advisors | $22.89M | 1.35 | 791,344 | -3.08% | -$728,833.46 | 0.01 | |
| 683 Capital Management Llc | $20.25M | 1.19 | 700,000 | -2.1% | -$433,950.00 | 2.27 | |
| Nuveen | $19.62M | 1.16 | 678,201 | +122.06% | +$10.78M | 0.01 | |
| Woodline Partners LP | $18.43M | 1.09 | 636,956 | New | +$18.43M | 0.17 | |
| Driehaus Capital Management LLC | $16.22M | 0.96 | 560,530 | +182.11% | +$10.47M | 0.16 | |
| Northern Trust | $15.59M | 0.92 | 538,995 | -2.03% | -$322,395.93 | <0.01 | |
| Goldman Sachs | $15.19M | 0.9 | 525,040 | +1.91% | +$284,092.60 | <0.01 | |
| Charles Schwab | $14.37M | 0.85 | 496,562 | +9.06% | +$1.19M | <0.01 | |
| Fidelity Investments | $13.48M | 0.8 | 466,085 | +0.03% | +$3,847.69 | <0.01 | |
| Mangrove Partners | $12.71M | 0.75 | 439,314 | 0% | +$0 | 0.13 | |
| Eversept Partners LP | $11.9M | 0.7 | 411,478 | -23.53% | -$3.66M | 0.9 | |
| Gratus Capital | $11.81M | 0.7 | 408,173 | +2.67% | +$306,715.86 | 0.57 | |
| Candriam S C A | $10.41M | 0.61 | 360,000 | -32.96% | -$5.12M | 0.07 | |
| Ubs Asset Management Americas Inc | $9.7M | 0.57 | 335,318 | +15.99% | +$1.34M | <0.01 | |
| Kennedy Capital Management Inc | $8.62M | 0.51 | 298,068 | -2.21% | -$194,467.45 | 0.18 | |
| Rafferty Asset Management Llc | $6.92M | 0.41 | 239,208 | +42.56% | +$2.07M | 0.02 | |
| JPMorgan Chase | $6.87M | 0.41 | 237,440 | -42.23% | -$5.02M | <0.01 | |
| Bank of America | $6.61M | 0.39 | 228,440 | +48.91% | +$2.17M | <0.01 | |
| Citigroup | $6.04M | 0.36 | 208,641 | +186.98% | +$3.93M | 0.01 | |
| Cibc World Markets Corp | $5.79M | 0.34 | 200,000 | New | +$5.79M | 0.04 | |
| Helm Capital Management LLC | $5.73M | 0.34 | 198,059 | New | +$5.73M | 0.17 | |
| Two Sigma Advisers LP | $5.69M | 0.34 | 196,700 | -11.4% | -$731,929.00 | 0.01 | |
| Silvercrest Asset Management Group Inc | $5.46M | 0.32 | 188,743 | +4.57% | +$238,585.71 | 0.04 | |
| BNY Mellon | $5.42M | 0.32 | 187,234 | -7.85% | -$461,231.02 | <0.01 | |
| UBS | $5.14M | 0.3 | 177,546 | +17.68% | +$771,823.50 | <0.01 | |
| American Century Investments | $4.64M | 0.27 | 160,320 | +318.11% | +$3.53M | <0.01 | |
| Two Sigma | $4.56M | 0.27 | 157,594 | -0.79% | -$36,133.57 | 0.01 | |
| Algert Global LLC | $4.28M | 0.25 | 147,843 | +95.15% | +$2.09M | 0.17 | |
| Walleye Capital | $3.88M | 0.23 | 134,114 | -27.67% | -$1.48M | 0.01 | |
| Jacobs Levy Equity Management | $3.73M | 0.22 | 129,011 | 0% | +$0 | 0.02 | |
| Artia Global Partners Lp | $3.6M | 0.21 | 124,440 | +10.77% | +$350,052.98 | 0.89 |